Compare Stocks: AMPH, OGN, GPCR, and TARS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.84 +0.4%	$20.48	$16.65 ▼ $29.78	$1.01B	0.92	517,336 shs	469,751 shs
GPCR Structure Therapeutics	$47.34 -1.0%	$50.81	$18.49 ▼ $94.90	$3.30B	-1.45	876,873 shs	621,429 shs
OGN Organon & Co.	$13.78 +0.1%	$13.60	$5.69 ▼ $13.78	$3.62B	1.52	5.66 million shs	3.92 million shs
TARS Tarsus Pharmaceuticals	$83.21 +0.5%	$65.08	$48.20 ▼ $85.25	$3.65B	0.54	744,913 shs	733,654 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+3.40%	+7.81%	+17.41%	+26.95%	-22.95%
GPCR Structure Therapeutics	+1.42%	-3.14%	-1.16%	+22.38%	+138.05%
OGN Organon & Co.	+0.04%	+0.04%	+1.55%	+2.84%	+46.46%
TARS Tarsus Pharmaceuticals	+11.76%	+17.14%	+34.96%	+37.16%	+41.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.84 +0.4%	$20.48	$16.65 ▼ $29.78	$1.01B	0.92	517,336 shs	469,751 shs
GPCR Structure Therapeutics	$47.34 -1.0%	$50.81	$18.49 ▼ $94.90	$3.30B	-1.45	876,873 shs	621,429 shs
OGN Organon & Co.	$13.78 +0.1%	$13.60	$5.69 ▼ $13.78	$3.62B	1.52	5.66 million shs	3.92 million shs
TARS Tarsus Pharmaceuticals	$83.21 +0.5%	$65.08	$48.20 ▼ $85.25	$3.65B	0.54	744,913 shs	733,654 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+3.40%	+7.81%	+17.41%	+26.95%	-22.95%
GPCR Structure Therapeutics	+1.42%	-3.14%	-1.16%	+22.38%	+138.05%
OGN Organon & Co.	+0.04%	+0.04%	+1.55%	+2.84%	+46.46%
TARS Tarsus Pharmaceuticals	+11.76%	+17.14%	+34.96%	+37.16%	+41.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-5.62% Downside
GPCR Structure Therapeutics	2.89	Moderate Buy	$110.91	134.28% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-17.27% Downside
TARS Tarsus Pharmaceuticals	2.78	Moderate Buy	$90.50	8.76% Upside

Current Analyst Ratings Breakdown

Latest AMPH, OGN, GPCR, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $23.00
8/12/2026	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$97.00 ➝ $100.00
8/7/2026	GPCR Structure Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$111.00
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$21.00 ➝ $20.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$19.00 ➝ $20.00
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$100.00 ➝ $97.00
8/7/2026	GPCR Structure Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$113.00 ➝ $110.00
8/3/2026	OGN Organon & Co.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/31/2026	TARS Tarsus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$100.00 ➝ $98.00
7/21/2026	TARS Tarsus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$90.00 ➝ $89.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$719.89M	1.41	$4.41 per share	5.40	$18.06 per share	1.32
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$19.45 per share	N/A
OGN Organon & Co.	$6.22B	0.58	$5.79 per share	2.38	$3.83 per share	3.60
TARS Tarsus Pharmaceuticals	$451.36M	8.09	N/A	N/A	$7.90 per share	10.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	14.11	9.20	4.42	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
GPCR Structure Therapeutics	-$141.20M	-$1.00	N/A	N/A	N/A	N/A	-25.56%	-24.31%	11/5/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.90	4.01	1.27	3.41%	88.97%	6.03%	11/9/2026 (Estimated)
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	145.98	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)

Latest AMPH, OGN, GPCR, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/6/2026	Q2 2026	GPCR Structure Therapeutics	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest AMPH, OGN, GPCR, and TARS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
GPCR Structure Therapeutics	N/A	20.75	20.75
OGN Organon & Co.	8.43	1.95	1.44
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
GPCR Structure Therapeutics	91.78%
OGN Organon & Co.	77.43%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
GPCR Structure Therapeutics	5.50%
OGN Organon & Co.	1.62%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
GPCR Structure Therapeutics	136	69.62 million	65.79 million	Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable
TARS Tarsus Pharmaceuticals	50	43.88 million	39.65 million	Optionable

AMPH, OGN, GPCR, and TARS Headlines

Recent News About These Companies

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 4,601 Shares of Stock

3 hours ago | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 5,387 Shares

3 hours ago | marketbeat.com

Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease

September 3 at 11:10 AM | globenewswire.com

The Manufacturers Life Insurance Company Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

September 3 at 4:32 AM | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 6.5% Higher - Should You Buy?

September 2 at 12:39 PM | marketbeat.com

Tarsus to Participate in Upcoming Investor Conferences

September 1 at 4:30 PM | globenewswire.com

Hsbc Holdings PLC Makes New $2.43 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

August 31 at 5:11 AM | marketbeat.com

Canada Pension Plan Investment Board Acquires Shares of 98,900 Tarsus Pharmaceuticals, Inc. $TARS

August 31 at 3:51 AM | marketbeat.com

Freestone Grove Partners LP Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Acquires New Position in Tarsus Pharmaceuticals, Inc. $TARS

August 28, 2026 | marketbeat.com

90,969 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Connor Clark & Lunn Investment Management Ltd.

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $7.91 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARS